McKesson Corporation 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for McKesson Corporation for the quarter ended June 30, 2007 (Fiscal Q1 2008). The company operates in two primary segments: Distribution Solutions (pharmaceutical and medical-surgical distribution) and Technology Solutions (healthcare software and services). The reporting period reflects a realignment of business segments effective April 1, 2007, and the adoption of FIN No. 48 regarding uncertainty in income taxes.
Key Financial Metrics
| Metric | Q1 2008 (Jun 30, 2007) | Q1 2007 (Jun 30, 2006) |
|---|---|---|
| Revenues | $24,528 million | $23,315 million |
| Gross Profit | $1,177 million | $996 million |
| Gross Margin | 4.80% | 4.27% |
| Operating Income | $356 million | $272 million |
| Net Income | $235 million | $184 million |
| Diluted EPS | $0.77 | $0.60 |
| Operating Cash Flow | $432 million | $297 million |
| Cash and Equivalents | $2,203 million | $2,000 million |
| Total Debt | $1,950 million | Filing text does not provide a clear comparative total debt figure for Q1 2007 |
| Working Capital | $3,298 million | Filing text does not provide a clear comparative working capital figure for Q1 2007 |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 5% year-over-year, driven by the Distribution Solutions segment (97% of total revenue) and the Technology Solutions segment (up 49%).
- Profitability: Net income rose 28% to $235 million. Gross profit margin expanded by 53 basis points to 4.80%, aided by higher buy-side margins, generic drug sales, and $14 million in antitrust settlement proceeds.
- Acquisitions: The acquisition of Per-Se Technologies (completed Jan 2007) significantly impacted the Technology Solutions segment, contributing to revenue and margin growth. Smaller acquisitions included RelayHealth and Sterling Medical Services.
- Divestitures: The company sold its Acute Care medical-surgical supply business for $160 million, resulting in a $61 million after-tax loss recorded in discontinued operations due to a $79 million goodwill write-off.
- Accounting Changes: Adoption of FIN No. 48 resulted in a $48 million reduction to retained earnings. Unrecognized tax benefits stood at $465 million.
Guidance, Outlook, and Risks
Management Commentary: Management attributes growth to market expansion, the Per-Se acquisition, and improved inventory management. Operating expenses increased 13% due to acquisitions and volume growth, but as a percentage of revenue, they remained relatively stable in the Distribution segment.
Liquidity and Capital: The company maintains a strong liquidity position with $2.2 billion in cash. A $1.0 billion share repurchase program was approved in April 2007; $257 million was utilized in Q1 2008, leaving $743 million available. The company issued $1 billion in long-term debt in March 2007 to fund the Per-Se acquisition and repay interim facilities.
Risks and Contingencies:
- Legal Proceedings: Ongoing securities litigation related to the 1999 HBOC accounting restatement remains pending. A qui tam action regarding Average Wholesale Price manipulation is under investigation by the Department of Justice and various states.
- Tax Audits: The IRS is auditing tax returns for 2000-2002, and Canadian authorities are examining 2002-2004. Potential cash payments for tax resolutions could reach $73 million in the next 12 months.
- Market Risks: Exposure to changes in healthcare regulations, reimbursement rates, and pharmaceutical pricing policies.
Investor Verification Checklist
- Per-Se Integration: Verify the ongoing financial contribution and integration costs of the Per-Se Technologies acquisition.
- Legal Exposure: Monitor the status of the HBOC securities litigation and the qui tam False Claims Act investigation regarding drug pricing.
- Tax Liabilities: Track the resolution of IRS and Canadian tax audits and potential impacts on unrecognized tax benefits ($465 million).
- Share Repurchases: Confirm the pace of the remaining $743 million share repurchase authorization.
- Discontinued Operations: Review the final impact of the Acute Care divestiture and any remaining liabilities.